We have used a combination of genetics and pharmacology to assess the effects of reduced DNA methyltransferase activity on ApcM~"-induced intestinal neoplasia in mice. A reduction in the DNA methyltransferase activity in Min mice due to heterozygosity of the DNA methyltransferase gene, in conjunction with a weekly dose of the DNA methyltransferase inhibitor 5-azadeoxycytidine, reduced the average number of intestinal adenomas from 113 in the control mice to only 2 polyps in the treated heterozygotes. Hence, DNA methyltransferase activity contributes substantially to tumor development in this mouse model of intestinal neoplasia. Our results argue against an oncogenic effect of DNA hypomethylation. Moreover, they are consistent with a role for ONA methyltransferase in the generation of the C to T transitions seen at high frequency in human colorectal tumors.
Introduction
Methylation of mammalian DNA is found as the covalent modification of the fifth carbon position of the pyrimidine ring of cytosines in CpG dinucleotides (Adams and Burdon, 1982; Gardiner-Garden and Frommer, 1987; Antequera and Bird, 1993) . Newly replicated DNA lacks this methylation in the nascent strand. Shortly after passage of the replication fork, a maintenance DNA methyltransferase methylates CpG dinucleotides on the newly synthesized strand at sites opposite to those methylated in the parental strand, thereby recreating the spectrum of methyl groups that existed prior to replication. So far, only one mammalian DNA (cytosine-5) methyltransferase enzyme (EC 2.1.1.37) has been identified and characterized (Bestor et al., 1988; Leonhardt and Bestor, 1993) . The carboxyterminal part of this protein shares sequence similarity with the conserved catalytic domain of prokaryotic DNA (cytosine-5) methyltransferases (Lauster et al., 1989; Posfai et al., 1989; Kumar et al., 1994) . The mammalian enzyme has an additional large amino-terminal extension :~These authors contributed equally to this work. lacking sequence similarity to other known DNA methyltransferases. This amino-terminal region is thought to be a regulatory domain and is known to contain signals necessary for the targeted localization of the enzyme to replication foci in the nucleus (Leonhardt et al., 1992) .
Changes in the pattern of DNA methylation have been correlated with a number of different processes in mammals. These include the expression level of genes (Yeivin and Razin, 1993) , chromatin structure (Keshet et al., 1986; Tazi and Bird, 1990; Kass et al., 1993) , the timing of DNA replication (Selig et al., 1988) , genomic imprinting (Barlow, 1993; Li et al., 1993) , and somatic X-chromosomal inactivation in females (Monk and Grant, 1990; Singer-Sam and Riggs, 1993) . Whether DNA methylation is a cause or a consequence of these processes remains in large part to be resolved. Nevertheless, it is clear that DNA methylation is an essential process in mammalian development, since mouse embryos deficient for the known DNA methyltransferase do not survive past mid gestation (Li et al., 1992) .
Several observations implicate a role for DNA methylation in cancer pathogenesis. Changes in the pattern of DNA methylation are commonly seen in human tumors (Jones and Buckley, 1990; Baylin et al., 1991; Spruck et al., 1993; Laird and Jaenisch, 1994) . Some loci tend to show increased levels of DNA methylation (Ohtani-Fujita et al., 1993; Issa et al., 1994) , whereas others are often hypomethylated Vogelstein, 1983a, 1983b; Goelz et al., 1985; Rao et al., 1989; Vorce and Goodman, 1991 ; Hanada et al., 1993) . The global level of DNA methylation is generally lower in tumor cells than in normal cells (Gama-Sosa et al., 1983; Feinberg et al., 1988) . This decrease in the overall level of DNA methylation is curious in light of the normal to high levels of DNA methyltransferase expression usually seen in tumor cells (Kautiainen and Jones, 1986; EI-Deiry et al., 1991; Issa et al., 1993) .
Some investigators have proposed that changes in DNA methylation contribute to oncogenesis by affecting the expression levels of proto-oncogenes and tumor-suppressor genes. Thus, DNA hypomethylation would allow increased expression of oncogenes; alternatively, DNA hypermethylation would help to silence tumor-suppressor genes. However, there is no direct evidence that either mechanism is operative in oncogenesis. Indeed, it is not even clear whether the changes in DNA methylation play a causal role in oncogenesis or whether they are merely a consequence of the transformed state of the tumor cell.
We have designed experiments in an attempt to distinguish between these alternatives. Using a combination of genetics and pharmacology, we have manipulated the levels of functional DNA methyltransferase in mice and determined the consequences for early steps of the neoplastic process. To do so, we used mice heterozygous for the multiple intestinal neoplasia (Min) mutation of the adenomatosis polyposis coil (Apc) gene (Min mice) as a model system to assess the role of DNA methylation in early neoplastic transformation (Moser et al., 1990; Suet al., 1992; Luongo et al., 1993 Luongo et al., , 1994 . Min mice develop multiple intestinal adenomas within the first few months of life (Moser et al., 1990 Luongo et al., 1994) . The number of intestinal polyps present in these mice at specific ages offered us a readily quantifiable measure of any effects that changes in DNA methylation might have on the incidence or rate of polyp formation.
Min mice carry a germline point mutation in the Apc, tumor-suppressor gene, the mouse homolog of the human APC gene, which, when present in mutant form in the human germ line, results in the syndrome of familial adenomatous polyposis coli (FAP; Su et aL, 1992) . FAP patients develop as many as 1000 benign colorectal polyps, some of which progress to malignancy if they are not removed Joslyn et al., 1991; Ichii et al., 1992; Miyoshi et al., 1992; Powell et al., 1992; Nakamura, 1993) . Similarly, mice carrying the Min allele of the Apc gene develop 100 or more intestinal polyps in the first 6 months of life. These polyps thus provide a model system for the early stages of human colorectal cancer, for which changes in DNA methylation patterns and in methyltransferase expression have been well documented (GamaoSosa et al., 1983; Feinberg et al., 1988; Silverman et al., 1989; EI-Deiry et al., 1991; Issa et al., 1993) .
We have previously generated mice carrying germline mutations in the DNA methyltransferase gene (Dnmt; Li et al., 1992 Li et al., , 1993 . Mouse embryos homozygous for either the Dnmt v allele (Li et al., 1992) or the stronger Dnmt s allele (Li et al., 1993) die before birth. Heterozygous mice have approximately half wild-type levels of DNA methyltransferase expression, which is apparently sufficient to maintain normal levels of DNA methylation (Li et al., 1992) . They appear otherwise phenotypically indistinguishable from their wild-type littermates.
In the present study, we further perturbed methyltransferase activity through use of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-dC), which is known to titrate out the enzyme activity by a covalent trapping mechanism (Santi et al., 1983 (Santi et al., , 1984 J0ttermann et al., 1994) . The combination of Dnmt heterozygosity and treatment with 5-aza-dC might be predicted to reduce the functional levels of DNA methyltransferase to below the threshold needed for maintenance of normal DNA methylation patterns. In this paper, we employ this combined strategy to study the effects of reduced DNA methyltransferase activity and consequent DNA methylation levels on the number of intestinal adenomas appearing in mice carrying the Min allele of the Apc gene.
Results

Effects of Decreased DNA Methyltransferase Activity on the Number of Intestinal Adenomas
To study the effects of DNA methyltransferase levels on intestinal polyp formation, we crossed 129/Sv Dnmt ~÷ female mice with C57BL/6 Apc MinI+ males. In addition, we determined the maximal dose of 5-aza-dC that mice could tolerate during an extended treatment protocol starting at 1 week of age. This dose (5 p+g of 5-aza-dC per 5 grams body weight) was given weekly by subcutaneous injection to the progeny of the cross described above. Control offspring were injected with phosphate-buffered saline (PBS) instead of 5-aza-dC. The injections were performed by investigators blind to the genotypes of the animals.
Previous experience indicated that at 100 days of age, a subset of intestinal polyps are just at the threshold of detectability in this strain background. During the subsequent 80 days, such polyps grow to a size that is readily visible. For this reason, mice were injected with either 5-aza-dC or PBS for 100 days (14 injections). The drug treatment was then discontinued, and the number of polyps was monitored 80 days later, allowing us to gauge the effects of DNA methyltransferase levels on polyp initiation and early growth during the first 100 days of life. In doing so, we avoided any cytotoxic or cytostatic effects that 5-aza-dC might have on the expansion of cell populations in the polyps during the growth period from 100 to 180 days. Figure 1 shows growth curves for the four different genotypes generated in this cross. As is apparent, the treatment with 5-aza-dC did not have a significant effect on the body weights of the mice.
A parallel cohort of animals was sacrificed at 100 days to determine the DNA methylation levels in the colon immediately following 5-aza-dC treatment. Figure 2 shows an analysis of DNA methylation levels of genomic colonic DNA derived from the Dnmt heterozygous and wild-type animals treated with or without 5-aza-dC. We compared DNA methylation levels by Southern blot analysis of re- Figure 2. DNA Methylation Analysis of Genomic Colonic DNA from Mice Treated Weekly with or without 5-aza-dC Mice derived from a cross between 129/Sv DnmP ~* females and a C57BL/6 male were injected weekly with 5-aza-dC for 100 days (14 weeks) or untreated. Genomic DNA from colons collected from 100-day-old mice was isolated as described previously (Laird et al., 1991) . Analysis of DNA methylation levels involved digestion of genomic DNA by the methylation-sensitive restriction enzyme Hpall, followed by hybridization with a centromeric minor satellite repeat probe (Chapman et al., 1984) for a reflection of the global DNA methylation status. The Dnmt genotypes and treatments are indicated above the lanes. Ungenotyped progeny were weighed and injected weekly with either 5 p.g of 5-aza-dC per 5 g of bodyweight or with its solvent, PBS. The injections were continued for 100 days (14 injections), after which the mice were monitored for an additional 80 days and then sacrificed. The entire intestine was excised immediately following sacrifice, fixed and washed with Bouin's fixative, and subjected to a systematic microscopic screen for polyp formation along the entire length of the intestine. The investigator counting the polyps was blind to beth Apc and Dnmt genotypes. The average number of polyps for each group is shown as a bar with the average also indicated above or within the bar; SEM is indicated by the thin error bars. The treatments, genotypes of the mice, and number of mice in each experimental group are indicated below the bars. All mice for this experiment were generated by the same limited number of parents and were maintained in the same room with the same food and cage conditions. striction digests with the DNA methylation-sensitive enzyme Hpall, hybridized with a centromeric minor satellite repeat probe (Chapman et al., 1984 ) (see Figure 2 ). In this assay, reduced levels of DNA methylation are revealed by a relative increase in lower molecular weight bands.
The analysis in Figure 2 shows that both Dnmt heterozygosity and 5-aza-dC treatment have a synergistically hypomethylating effect on colonic DNA. The effect of 5-aza-dC appears to be stronger than that of Dnmt heterozygosity. The number of intestinal polyps at sacrifice at 180 days was determined by examination of the mucosa over the entire length of the intestine under a dissecting microscope. Figure 3 shows the averaged results obtained for the various experimental groups. Mice wild-type at the Apc locus did not develop intestinal polyps with any combination of Dnmtgenotype or drug treatment. Ape "Mi~ heterozygous mice developed an average of 113 polyps in the Dnmt */÷ PBS control group. Dnmt s heterozygosity reduced the number to a statistically significant lower average of only 46 polyps (p ~< 0.001 in Student's t test). A more pronounced effect was seen in theApc Mj "~+ heterozygous mice treated with 5-aza-dC. Treatment of Dnmt wild-type mice with 5-aza-dC reduced the number of polyps from 113 to an average of 20. The combined effects of Dnmt heterozygosity and 5-aza-dC treatment resulted in only 2 intestinal adenomas.
The decrease in polyp number in mice having reduced levels of active DNA methyttransferase was opposite to the result expected for a model in which global DNA hypomethylation contributes to the neoplastic process in colorectal cancer. The effect of DNA methyltransferase on Min-induced intestinal neoplasia appeared to be predominantly on polyp number rather than size or morphology. The adenomas in the Dnmt ~ heterozygous mice appeared to be somewhat smaller, but this was not confirmed by a systematic morphometric analysis. We did not find any evidence for a difference in the state of differentiation or in the progression of the adenomas from the different experimental groups, as assessed by histological examination of the polyps in Min mice from all four cohorts.
Significantly, a substantial reduction in polyp number was achieved in the absence of 5-aza-dC treatment. A slight reduction in DNA methylation levels in untreated Dnmt heterozygous colonic DNA is also evident in Figure  2 (see lanes 3 and 4). Reduced DNA methylation and the decreased number of intestinal polyps, seen in the context of Apc uirv* heterozygosity, are the first examples of observed phenotypic differences between Dnmt wild-type mice and D n m~ + heterozygotes. Furthermore, these results demonstrate that Dnmt is a genetic modifier of the Min phenotype. It is the second such modifier to be described, the first being the AKR/J allele of the modifier of Min-1 (Mom-1; Moser et al., 1992; Dietrich et al., 1993) ; however, Dnmt and Morn-1 are distinct loci. Mom-1 maps to mouse chromosome 4 , whereas Dnmt maps to mouse chromosome 9 (Copeland et al., 1993) . In all cases, the injections were continued until the mice were 100 days old. The mice were sacrificed at either 100, 150, or 180 days of age, as indicated, and subjected to an intestinal polyp count as described for Figure 3 . The sizes of the experimental groups were as follows: open squares, n = 6; closed squares, n = 9; open circles, n = 2, n = 5, and n = 13 for 100, 150, and 180 days, respectively; closed circles, n = 3, n = 2, and n = 12 for 100, 150, and 180 days, respectively. The treatments are indicated schematically at the bottom of the figure. matic effect on the number of intestinal polyps, the available evidence did not provide strong indications whether the effect was attributable to an early influence on the rate of initiation of adenoma formation or, alternatively, to a later cytostatic or cytotoxic influence of 5-aza-dC on already initiated adenomas. An indication that 5-aza-dC affects polyp initiation came from experiments in which drug treatment was delayed until day 50 in a cohort of C57BL/6 Min mice. In this strain background, the majority of polyps become visible between 50 and 100 days of age (A. F., unpublished data; Moser et al., 1990 Moser et al., , 1992 . As can be seen in Figure 4 , the delay in the start of 5-aza-dC treatment abolished its inhibitory effect on the number of polyps counted at day 100. Furthermore, there was no readily apparent difference in the size of polyps from mice that had received a delayed 5-aza-dC treatment compared with their PBS-treated littermates. These results suggested that the initiation of polyp formation occurs prior to day 50 and is followed by a period of expansion of cell populations in already initiated polyps in the subsequent 50 day period. To exert its effects on polyp number, 5-aza-dC must be present during this critical formative period, rather than during the subsequent proliferative phase. As such, we consider it unlikely that 5-aza-dC acts through a cytotoxic or cytostatic effect on the cells in already formed adenomatous cell clones. It is also apparent from Figure 4 that the majority of polyps at day 180 in mice treated from day 0 to 100 appeared only after cessation of drug treatment. These adenomas may represent rapidly growing polyps initiated after Intestines from randomly chosen mice from the experiment shown in Figure 3 were washed in PBS. Large, distinct adenomas were excised and processed for DNA isolation as described in Figure 2 . In addition, normal intestinal mucosa adjacent to the polyp was excised and is shown immediately to the right of each polyp in the figure. The normal tissue in lane 9 is the control for both lanes 7 and 8. Lanes 10 and 11 contain samples derived from tail biopsies as control DNAs. Lane 10 is from an Apc ÷' mouse. Lane 11 is from an Apc =~+ mouse. PCR reactions were performed as described in Experimental Procedures. The PCR products were gel-separated, blotted, and hybridized consecutively with oligodeoxynucleotide probes specific for the Ape w~ allele (A) and for the Apc+ allele (B), and finally with a probe recognizing both alleles (C).
Early Administration of 5-aza-dC Is Required for Its
day 100, since the experiments described above argue against an inhibitory effect of 5-aza-dC on the expansion of previously initiated polyps. This raises the possibility that continued treatment with 5-aza-dC could lead to the virtual elimination of polyp formation.
Loss of Heterozygosity at the Apc Locus
The precise nature of the interactions of DNA methylation and the mutant Apc M~" allele in tumor development were not made clear by these analyses. The paradigm developed from extensive study of the Apc and similarly behaving tumor-suppressor genes dictates that loss of the wildtype Apc allele should accompany tumor development (Scrable et al., 1990; Weinberg, 1991; Boynton et al., 1992; Ichii et al., 1992; Levine, 1993; Nakamura, 1993; Brewster et al., 1994; Tamura et al., 1994) . We wished to ascertain that this genetic mechanism operated in all of the experimental groups studied, regardless of the status of their Dnmt locus or their history of 5-aza-dC treatment. We tested polyps from the different cohorts for loss of heterozygosity at the site of the Apc Mj" mutation. A segment of DNA encompassing the mutation was amplified from DNA derived from polyps and from adjacent normal tissue. The polymerase chain reaction (PCR) products were hybridized consecutively with oligodeoxynucleotide probes specific for the Apc M~" allele and for the Apc ÷ allele, and finally with a probe recognizing both alleles. The relative strengths of the signals derived from the Apc M~n-and Apc÷-specific probes were calculated after quantitation on a phosphoimager and subsequent normalization to the signal deriving from the probe recognizing both alleles. Loss of heterozygosity in polyps should reveal a reduction Intestines from randomly chosen mice from the experiment shown in Figure 1 and Figure 2 were washed in PBS. Large, distinct adenomas were excised and processed for DNA isolation as described previously (Laird et al., 1991) . In addition, normal intestinal mucosa adjacent to the polyp was excised as a reference standard. PCR reactions were performed as described in Experimental Procedures. The PCR products were gelseparated, blotted, and hybridized consecutively with oligodeoxynucleotide probes specific for the Apc M~ allele and for the Apc* allele, and finally with a probe recognizing both alleles. The relative hybridization signals were quantitated with a phosphoimager. Signals were first normalized using the hybridization signal specific for both alleles (Apc-Uni probe). Subsequently, the ratio of Apc ~ to Apc ÷ hybridization was calculated. Most polyps had ratios of more than 2.0. The four polyps defined as not showing loss of heterozygosity had ratios between 0.9 and 1.1, within the range seen for all normal adjacent tissues.
in the relative level of the Apc ÷ signal and an increase in the relative level of the Apc Mj n signal in polyps compared with normal adjacent tissue. Figure 5 shows the analysis of a representative series of polyps from Dnmt wild-type mice, along with control DNAs derived from tail biopsies from Apc Mi n/+ and Apc +/+ mice. The results obtained for all polyps analyzed are summarized in Table 1 . Loss of the wild-type allele was seen in the majority of polyps derived from all experimental groups. These results are in agreement with the loss of heterozygosity at the APC locus seen as an early event in human cancer (Boynton et al., 1992; Ichii et al., 1992; Nakamura, 1993; Brewster et al., 1994; Tamura et al., 1994) . The high frequency of loss of heterozygosity at the Apc locus is close to the 100% loss of Apc heterozygosity in ApcMJ"-induced intestinal adenomas found by Luongo et al. (1994) .
We found several polyps that lacked any sign of loss of heterozygosity (see Figure 5 and Table 1 ). Such cases do not seem to be overrepresented in any particular cohort. It is possible that these polyps have lost the function of the wild-type allele through another mechanism, such as the acquisition of a mutation elsewhere in the Apc gene. Alternatively, loss of function of the wild-type Apc protein may not be an absolute requirement for polyp formation. In support of this, we have recently obtained evidence for a dominant mode of action for the truncated protein product of the Apc uj" allele by comparing the phenotypes of mice heterozygous for different Apc mutations (A. F., unpublished data).
Discussion
DNA Methyltransferase Is an Oncogenic Determinant in Min.lnduced Intestinal Neoplasia
Mice carrying the Min allele of the Apc gene are predisposed to intestinal polyps that become readily observable at several months of age (Moser et al., 1990 Luongo et al., 1994) . As demonstrated here, the number of these polyps can be reduced in two ways: through treatment with the drug 5-aza-dC or through introduction of a mutant allele of the DNA methyltransferase gene. These two perturbants are also united by a common biochemical mechanism of action. When incorporated into DNA, 5-aza-dC causes the formation of stable covalent adducts between DNA methyltransferase and the DNA, resulting in the depletion of free, active enzyme from the cell (Santi et al., 1983 (Santi et al., , 1984 J0ttermann et al., 1994 ). The Dnmt s mutation achieves the same end result through inactivation of a chromosomal gene copy encoding this enzyme. Indeed, both Dnmt heterozygosity and 5-aza-dC treatment result in a reduction of genomic DNA methylation levels as represented by an analysis of centromeric repeat sequences.
The genesis of intestinal polyps depends upon the frequency with which they are initiated and their subsequent ability to proliferate to a size that makes them visible under the dissecting microscope. Thus, the present phenomena need to be interpreted in light of these two events governing observed polyp number. The initiation of polyp formation would appear to depend upon low frequency stochastic events, in that the number of distinct clones of polyps is many orders of magnitude lower than the number of cells in the target tissue. This stochastic event could involve the loss of the wild-type Apc allele that initially coexists with the mutant Apc Mr" allele in all cells of the intestinal epithelium. While this is an attractive idea, our results suggest that there are events other than the loss of Apc heterozygosity that can be rate-limiting for polyp formation. This is apparent from the fact that the effects of DNA methyltransferase levels on polyp number do not seem to be mediated through a change in the rate of loss of Apc heterozygosity. If such were the case, then we should have found a decreased rate of loss of Apc heterozygosity in the mice with reduced numbers of polyps (Table 1) . This should have shown up as a relative increase in the number of polyps without loss of Apc heterozygosity. Since this is not what we observed, we suggest that the effects of DNA methyltransferase levels are exerted through a rate-limiting process other than loss of Apc heterozygosity.
An early, rate-limiting stochastic event rather than a later, proliferative process would appear to be the target of inhibition by the 5-aza-dC that we have administered to these mice. We conclude this from our observations of the comparative effects of this drug administered at weekly intervals beginning either at the first week of life or only at day 50. The first protocol involving early administration severely depresses polyp number; in contrast, delayed administration has no effects on polyp number or size. During days 50-100 of life, these polyps undergo a size proliferation that causes them to become visible in the dissecting microscope. Therefore, we conclude that 5-azadC has minimal effects on proliferation but profound effects on the earlier initiation, which must occur well before day 50.
Consistent with this conclusion is our recent work that documents the cytostatic/cytotoxic effects of 5-aza-dC treatment. We have found that these antiproliferative effects are not mediated through loss of DNA methylation per se, but rather through the formation of stable covalent complexes between the DNA methyltransferase enzyme and the incorporated cytosine analog (Santi et al., 1983 (Santi et al., , 1984 J0ttermann et al., 1994) . Consequently, cells that have lower levels of DNA methyltransferase are less sensitive to growth inhibition by 5-aza-dC (J0ttermann et al., 1994) . In the present study, we observed the exact opposite: the ability of 5-aza-dC to suppress polyp formation was stronger in mice with levels of DNA methyltransferase reduced owing to the Dnmt s mutation.
DNA Methyltransferase Levels and Polyp Formation: Possible Mechanisms
Studies on DNA methylation changes in human cancer cells have presented a somewhat confusing picture. Hypotheses to explain the involvement of DNA methylation in cancer fall broadly into two classes. The first type proposes that changes in DNA methylation contribute to the oncogenic process through effects on gene expression. The other type argues that the major role of DNA methylation in cancer is mediated through the disproportionately high rate of mutation of methylated cytosine residues.
Among the models that address gene expression-mediated effects of DNA methylation in oncogenesis, two opposing mechanisms have been proposed. One model proposes that the commonly observed global DNA hypomethylation in human tumors is of selective advantage to the tumor cell through facilitated proto-oncogene expression (Feinberg and Vogelstein, 1983b; Rao et al., 1989; Vorce and Goodman, 1991 ; Hanada et al., 1993) . In the alternative model, high expression of DNA methyltransferase is thought to drive hypermethylation of specific loci such as tumorsuppressor genes or genes specific to differentiated cell types (Kautiainen and Jones, 1986; Greger et al., 1989; Silverman et al., 1989; Baylin et al., 1991; EI-Deiry et al., 1991; Issa et al., 1993 Issa et al., , 1994 Ohtani-Fujita et al., 1993) . This would allow outgrowth of undifferentiated neoplastic cells. The suppression of polyp formation by the reduction of DNA methyltransferase and DNA methylation levels is inconsistent with the first mechanism, which favors an oncogenic effect of DNA hypomethylation. Our results do lend support for thetumor-suppressor gene hypermethylation model, although one would have to argue that reduction of global DNA methyltransferase levels would affect local DNA hypermethylation. It is not clear how regional DNA hypermethylation is achieved in the face of global DNA hypomethylation.
In contrast to the gene expression-mediated models discussed above, the mutation-mediated models propose that DNA methylation contributes to oncogenesis through a disproportionately high mutation rate of 5-methylcytosine residues Spruck et al., 1993; Laird and Jaenisch, 1994) . Deamination at cytosine-4 of both methylated and unmethylated cytosine residues is known to occur spontaneously to yield thymine and uracil, respectively (Wang et al., 1982; Ehrlich et al., 1986; Frederico et al., 1990; Shen et al., 1994) . A uracil residue is ultimately substituted by thymine if it is not repaired prior to DNA replication. The occurrence of C to T transition mutations is considerably higher for 5-methylcytosine than for unmethylated cytosine residues. In fact, mutations of this sort are of significance in human tumorigenesis. Approximately 47% of the characterized point mutations in the p53 tumor-suppressor gene in colorectal tumors are nucleotide transitions within CpG dinucleotides, the target for DNA methylation (Greenblatt et al., 1994) . This frequency contrasts with the fact that CpG dinucleotides occur within the coding region of the wild-type human p53 gene at a frequency of 3.3% (39 out of 1179). The target size for mutagenesis at either nucleotide within CpG dinucleotides is therefore 6.60. Mutations at CpG dinucleotides are thus overrepresented approximately 7-fold in human colorectal tumors (Greenblatt et al., 1994) . Reduced cellular DNA methylation levels could lead to a lower rate of spontaneous C to T transitions. If rate-limiting mutational events, in addition to the loss of the wild-type Apc allele, were required for polyp formation, then a reduced rate of C to T transitions could result in a lower number of intestinal polyps.
The high mutation rate of methylated cytosine residues might also be achieved through a different mechanism that directly involves the DNA methyltransferase enzyme (reviewed in Laird and Jaenisch, 1994) . The covalent enzyme adduct formed between DNA methyltransferase and its substrate cytosine has been found to destabilize the amine group of the latter, resulting in an enhanced rate of deamination. Normally, this adduct is formed only ephemerally; the presence of the methyl donor S-adenosyl methionine (SAM) results in the rapid completion of the reaction and the disappearance of this destabilized intermediate. But, in the absence of sufficient amounts of SAM, the half-life of this intermediate may be substantially extended, resulting, in turn, in a great increase in cytosine deamination. This has been demonstrated experimentally for a prokaryotic DNA methyltransferase (Shen et al., 1992) . If such a mechanism were also applicable to the mammalian enzyme, limiting levels of SAM in the intestinal epithelium could result in a mutagenic process with an activity correlating with DNA methyltransferase levels. We note in passing that diets deficient in methionine have been reported to predispose humans to increased numbers of colonic polyps (Giovannucci et al., 1993) . Whether this is only an adventitious association or derives from a mechanism associated with DNA methyltransferase-mediated deamination and mutation is not revealed by presently available evidence. Experiments in rodents have shown that methyl-deficient diets, which lead to SAM depletion, enhance liver tumorigenesis (Mikol et al., 1983; Shivapurkar et al., 1986) .
Recently, the laboratories of Peter Jones and Richard Roberts have found evidence for yet another mechanism through which DNA methyltransferase enzymes could exert an effect on cytosine mutation rates (Yang et al., personal communication; Klimasauskas and Roberts, personal communication) . Both groups have demonstrated that a prokaryotic DNA methyltransferase is capable of high affinity binding to GU mismatches. In addition, the enzyme is then capable of converting the uracil residue to thymine by the transfer of a methyl group. GU mismatch repair would be inhibited directly by the binding of the DNA methyltransferase as well as indirectly by the conversion of U to T, which is less efficiently repaired in a mismatch with G (Shenoy et al., 1987; Brown and Brown, 1989) . Whether the mammalian DNA methyltransferase exhibits similar properties remains to be seen.
Experiments currently under way are designed to examine the precise effects of 5-azaodC treatment and the inactivated Dnmt allele on the mutational rate of genes within specific tissues of the mouse. Such experiments should indicate whether these perturbants directly suppress mutation rate, and in turn have profound effects on the rate of polyp initiation in Min mice.
Experimental Procedures
Mice
Mice were maintained in the facilities of the Whitehead Institute for Biomedical Research and were fed ad libitum. Their diet consisted of Agway Prolab Rat, Mouse, and Hamster 3000 chow, which has a crude protein content of at least 22°/0, a crude fat content of at least 5%, and a crude fiber content of at most 5%. C57BL/6 Apc 'a~ mice were purchased from the Jackson Laboratories, Bar Harbor, Maine. 129/ Sv Dnmt ~+ mice were generated in our facilities (Li et al., 1992 (Li et al., , 1993 .
5-aza-dC Injections
129/Sv Dnmt s~ female mice were crossed to C57BL/6 Apc Mi~ males. Progeny were weighed on a Mettler balance and injected weekly with either 5 p~g of 5-aza-dC per 5 g of body weight (rounded to the nearest multiple of 5 g) or with its solvent, PBS. The 5-aza-dC (Sigma Chemical Co., St. Louis, MO, catalog number A-3656) was prepared as a 2.5 mg/ml solution in PBS and stored in aliquots at -70°C. Injections were performed with a 100 p.I Hamilton 700 series syringe with a Luer tip and a PB600 dispenser attachment, allowing injection of 50 discrete 2 p_l volumes. The injections were started at 7 days of age and continued for 100 days (14 injections), after which the mice were monitored for an additional 80 days and then sacrificed.
Polyp Analysis
The entire intestine~was excised immediately following sacrifice, fixed, and washed with Bouin's fixative and subjected to a systematic micro* scopic screen for polyp formation along the entire length of the intestine. Adenomas were counted if they had reached a size of at least two villi. The investigator counting the adenomas was blind to both Apc and Dnmt genotypes. Adenomas destined for DNA analysis were microdissected from intestines that had been washed with PBS, before being fixed with Bouin's fixative.
DNA Methylation Analysis
DNA was prepared from frozen tissue samples as described previously (Laird et al., 1991) . Genomic DNA (5 I~g) was digested with the restriction enzyme Hpall (New England Biolabs, Beverly, MA) as specified by the manufacturer. After agarose gel electrophoresis followed by Southern blotting, the filters were hybridized with a 150 bp probe containing centromeric minor satellite repeat sequences derived from plasmid pMR150 (Chapman et al., 1984) .
Allellc Loss Analysis
The murine Apc cDNA sequence was obtained from GenBank (accession no. M88127; Suet al., 1992) . A 619 bp fragment spanning the site of the Min mutation was amplified from genomic DNA samples by PCR using oligonucleotides MAPC-15 (Apc sequence 2859-2841; 5'-TTCCACTTTGGCATAAGGC-3~ and MAPC-9 (APC sequence 2241-2258; 5'-GCCATCCC'I-I'CACGTTAG-3'). The PCR products were gel-fractionated on a 2% agarosa gel, Southern blotted, and hybridized with three probes in sequential hybridizations. The three probes were Min-Sensa (Apc sequence 2542-2556; 5'-AGAAGT-TAGGAGAGA-3'), Apc-Sense (Apc sequence 2542-2556; 5'-AGAAG-TTTGGAGAGA-3'), and Apc-Uni (Apc sequence 2530-2544; 5'-TCTG-AGAAAGACAGA-3'). Min-Sense hybridizes specifically to the Apc '~ mutant allele, while Apc-Sensa hybridizes specifically to the wild-type allele. Apc-Uni hybridizes to both alleles. The hybridization signals were quantitated using a Fuji phosphoimager. The signal levels in the Apc-Uni hybridization were used to normalize the amount of DNA in each lane.
